Images

In vivo quantification of tau can be performed using tau-PET (PET: positron emission tomography). This illustration represents the stages of tau pathology measured by PET.

Currently, CSF p-tau181, Aβ42/40, and total tau are used to diagnose AD in clinical practice. P-tau217 has recently gained attention due to its high sensitivity and specificity for AD.

Representative figures of Fluorodeoxyglucose PET ([18F]FDG-PET) images in a control subject and a patient with advanced Alzheimer’s Disease (AD).

Examples of amyloid-negative and amyloid-positive positron emission tomography (PET) scans. In this figure, the amyloid-PET ligand [18F]AZD4694 is shown.

Schematic representation of a healthy brain and Alzheimer’s disease (AD) brain. Compared to the healthy brain, the brain with AD, as the disease progresses, features an atrophied cerebral cortex, shrinkage of the hippocampus, and enlargement of the ventricles.

This image shows the four stages of biomarker discovery from Step 1: Identifying Targets to Step 4: Ensuring Clinical Benefit.